Esophageal dysmotility in patients undergoing photodynamic therapy

N. Malhi-Chowla, H. C. Wolfsen, K. R. DeVault

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective: To study the esophageal motility of patients with esophageal adenocarcinoma or Barrett esophagus with high-grade dysplasia before and after photodynamic therapy. Patients and Methods: In this prospective study conducted between January 1998 and October 1999, esophageal motility testing of the lower esophageal sphincter and esophageal body was performed with a water-perfused catheter, 2 days before and at least 3 weeks after patients underwent photodynamic therapy for esophageal adenocarcinoma or Barrett esophagus. Results were classified as normal motility, ineffective esophageal motility, or aperistalsis. Results: Twenty-three patients were studied, 13 with carcinoma and 10 with Barrett esophagus. Overall, 11 patients (48%) had normal motility, 6 (26%) had ineffective esophageal motility, and 6 (26%) had aperistalsis. Five patients with aperistalsis had carcinoma. Follow-up tracings after photodynamic therapy found that 6 patients (26%) had normal motility, 7 (30%) had ineffective esophageal motility, and 10 (43%) had aperistalsis. Conclusions: Esophageal dysmotility is common in patients with esophageal adenocarcinoma or Barrett esophagus. Photodynamic therapy may worsen esophageal motility in some patients. Dysphagia after photodynamic therapy therefore may be related to underlying esophageal dysmotility and may not always be caused by stricture or underlying carcinoma.

Original languageEnglish (US)
Pages (from-to)987-989
Number of pages3
JournalMayo Clinic Proceedings
Volume76
Issue number10
StatePublished - 2001

Fingerprint

Esophageal Motility Disorders
Photochemotherapy
Barrett Esophagus
Carcinoma
Lower Esophageal Sphincter
Deglutition Disorders
Pathologic Constriction
Catheters
Prospective Studies

Keywords

  • IEM = ineffective esophageal motility
  • LES = lower esophageal sphincter
  • PDT = photodynamic therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Malhi-Chowla, N., Wolfsen, H. C., & DeVault, K. R. (2001). Esophageal dysmotility in patients undergoing photodynamic therapy. Mayo Clinic Proceedings, 76(10), 987-989.

Esophageal dysmotility in patients undergoing photodynamic therapy. / Malhi-Chowla, N.; Wolfsen, H. C.; DeVault, K. R.

In: Mayo Clinic Proceedings, Vol. 76, No. 10, 2001, p. 987-989.

Research output: Contribution to journalArticle

Malhi-Chowla, N, Wolfsen, HC & DeVault, KR 2001, 'Esophageal dysmotility in patients undergoing photodynamic therapy', Mayo Clinic Proceedings, vol. 76, no. 10, pp. 987-989.
Malhi-Chowla N, Wolfsen HC, DeVault KR. Esophageal dysmotility in patients undergoing photodynamic therapy. Mayo Clinic Proceedings. 2001;76(10):987-989.
Malhi-Chowla, N. ; Wolfsen, H. C. ; DeVault, K. R. / Esophageal dysmotility in patients undergoing photodynamic therapy. In: Mayo Clinic Proceedings. 2001 ; Vol. 76, No. 10. pp. 987-989.
@article{0a447d60b43f4678ab3770d78985f417,
title = "Esophageal dysmotility in patients undergoing photodynamic therapy",
abstract = "Objective: To study the esophageal motility of patients with esophageal adenocarcinoma or Barrett esophagus with high-grade dysplasia before and after photodynamic therapy. Patients and Methods: In this prospective study conducted between January 1998 and October 1999, esophageal motility testing of the lower esophageal sphincter and esophageal body was performed with a water-perfused catheter, 2 days before and at least 3 weeks after patients underwent photodynamic therapy for esophageal adenocarcinoma or Barrett esophagus. Results were classified as normal motility, ineffective esophageal motility, or aperistalsis. Results: Twenty-three patients were studied, 13 with carcinoma and 10 with Barrett esophagus. Overall, 11 patients (48{\%}) had normal motility, 6 (26{\%}) had ineffective esophageal motility, and 6 (26{\%}) had aperistalsis. Five patients with aperistalsis had carcinoma. Follow-up tracings after photodynamic therapy found that 6 patients (26{\%}) had normal motility, 7 (30{\%}) had ineffective esophageal motility, and 10 (43{\%}) had aperistalsis. Conclusions: Esophageal dysmotility is common in patients with esophageal adenocarcinoma or Barrett esophagus. Photodynamic therapy may worsen esophageal motility in some patients. Dysphagia after photodynamic therapy therefore may be related to underlying esophageal dysmotility and may not always be caused by stricture or underlying carcinoma.",
keywords = "IEM = ineffective esophageal motility, LES = lower esophageal sphincter, PDT = photodynamic therapy",
author = "N. Malhi-Chowla and Wolfsen, {H. C.} and DeVault, {K. R.}",
year = "2001",
language = "English (US)",
volume = "76",
pages = "987--989",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Esophageal dysmotility in patients undergoing photodynamic therapy

AU - Malhi-Chowla, N.

AU - Wolfsen, H. C.

AU - DeVault, K. R.

PY - 2001

Y1 - 2001

N2 - Objective: To study the esophageal motility of patients with esophageal adenocarcinoma or Barrett esophagus with high-grade dysplasia before and after photodynamic therapy. Patients and Methods: In this prospective study conducted between January 1998 and October 1999, esophageal motility testing of the lower esophageal sphincter and esophageal body was performed with a water-perfused catheter, 2 days before and at least 3 weeks after patients underwent photodynamic therapy for esophageal adenocarcinoma or Barrett esophagus. Results were classified as normal motility, ineffective esophageal motility, or aperistalsis. Results: Twenty-three patients were studied, 13 with carcinoma and 10 with Barrett esophagus. Overall, 11 patients (48%) had normal motility, 6 (26%) had ineffective esophageal motility, and 6 (26%) had aperistalsis. Five patients with aperistalsis had carcinoma. Follow-up tracings after photodynamic therapy found that 6 patients (26%) had normal motility, 7 (30%) had ineffective esophageal motility, and 10 (43%) had aperistalsis. Conclusions: Esophageal dysmotility is common in patients with esophageal adenocarcinoma or Barrett esophagus. Photodynamic therapy may worsen esophageal motility in some patients. Dysphagia after photodynamic therapy therefore may be related to underlying esophageal dysmotility and may not always be caused by stricture or underlying carcinoma.

AB - Objective: To study the esophageal motility of patients with esophageal adenocarcinoma or Barrett esophagus with high-grade dysplasia before and after photodynamic therapy. Patients and Methods: In this prospective study conducted between January 1998 and October 1999, esophageal motility testing of the lower esophageal sphincter and esophageal body was performed with a water-perfused catheter, 2 days before and at least 3 weeks after patients underwent photodynamic therapy for esophageal adenocarcinoma or Barrett esophagus. Results were classified as normal motility, ineffective esophageal motility, or aperistalsis. Results: Twenty-three patients were studied, 13 with carcinoma and 10 with Barrett esophagus. Overall, 11 patients (48%) had normal motility, 6 (26%) had ineffective esophageal motility, and 6 (26%) had aperistalsis. Five patients with aperistalsis had carcinoma. Follow-up tracings after photodynamic therapy found that 6 patients (26%) had normal motility, 7 (30%) had ineffective esophageal motility, and 10 (43%) had aperistalsis. Conclusions: Esophageal dysmotility is common in patients with esophageal adenocarcinoma or Barrett esophagus. Photodynamic therapy may worsen esophageal motility in some patients. Dysphagia after photodynamic therapy therefore may be related to underlying esophageal dysmotility and may not always be caused by stricture or underlying carcinoma.

KW - IEM = ineffective esophageal motility

KW - LES = lower esophageal sphincter

KW - PDT = photodynamic therapy

UR - http://www.scopus.com/inward/record.url?scp=0034779610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034779610&partnerID=8YFLogxK

M3 - Article

C2 - 11605700

AN - SCOPUS:0034779610

VL - 76

SP - 987

EP - 989

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -